Study Summary
This trial found that RIC followed by a match aploidentical donor peripheral blood stem cell transplantation can be a feasible and effective treatment for older adults or those patients that are otherwise unfit for myeloablative conditioning.
- Advanced Hematologic Malignancies
- Allogeneic Bone Marrow Transplant
- Leukemia
- Myelodysplastic Syndrome
- Myeloproliferative Disorder
- Acute Leukemia
Treatment Effectiveness
Study Objectives
5 Primary · 8 Secondary · Reporting Duration: 2 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Arm A: Matched related/matched unrelated donor transplantation
1 of 2
Arm B: Haploidentical transplantation
1 of 2
Experimental Treatment
24 Total Participants · 2 Treatment Groups
Primary Treatment: Melphalan · No Placebo Group · Phase 1
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 75 · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there other peer-reviewed trials that utilize Filgrastim granulocyte colony-stimulating factor (G-CSF)?
"At this moment, there are 1140 Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent clinical trials underway with 206 in Phase 3. Many of these medical studies are based in Philadelphia, Pennsylvania, but there are 31564 locations running trials for Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent." - Anonymous Online Contributor
Does this research project have age restrictions?
"This study requires that participants are over 18 and younger than 75." - Anonymous Online Contributor
Has the FDA given their thumbs up to Filgrastim granulocyte colony-stimulating factor (G-CSF)?
"Given that Phase 1 trials have limited data to support safety and efficacy, our team rates Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent as a 1." - Anonymous Online Contributor
Why is Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent a common medication?
"Filgrastim granulocyte colony-stimulating factor (G-CSF) is an effective treatment for dermatitis, atopic, multiple sclerosis, and leukemia, myelocytic, acute." - Anonymous Online Contributor
What are the benefits that researchers hope to achieve with this study?
"The primary outcome of this clinical trial, which will be measured over the course of baseline, day +30, 60, 90, 180, year 1 and year 2 is to The incidence and timing of primary graft failure. Secondary objectives include Steroid-refractory acute GVHD which is defined as Steroid refractory acute GVHD will be defined as per the EBMT-NIH-CIBMTR Task Force position statement, Acute GVHD (all grades) which is defined as Acute GVHD (all grades) will be reported, and Non-relapse mortality (NRM)" - Anonymous Online Contributor
Are researchers currently looking for participants in this trial?
"The official website for this clinical trial shows that it is still recruiting patients. This trial was first announced on September 7th, 2021 and was edited October 19th, 2022." - Anonymous Online Contributor
Could I be a part of this research project if I qualify?
"This study is seeking 24 participants aged 18-75 who have myelodysplastic syndromes. Eligible participants must also meet the following criteria: histopathologically-confirmed acute myeloid, lymphoid, or mixed phenotype leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi) or beyond first complete remission (CR1) without the presence of minimal residual disease; not in morphologic CR with bone marrow infiltration by leukemic blasts of ≤10%; or in morphologic CR with evidence of minimal residual disease positivity by either multiparametric flow cytometric analysis or by" - Anonymous Online Contributor